Close

Chronic lymphocytic leukemia (CLL)

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the West, and about 30% of all reported leukemias is CLL. This disease occurs when the patient's bone marrow produces too many abnormal white blood cells (WBC), or lymphocytes, which never become normal, infection fighting WBC. As the amount of these unhealthy lymphocytes increasing, they interfere with the normal production process of other important blood cells. More than 50% of CLL patients are older than 70, and individuals younger than 40 are rarely diagnosed with this disease. Researchers are not certain what are the exact reasons that start CLL, however, exposure to chemicals (e.g. Agent Orange druing the Vietnam War), family history of CLL, getting treated with immunosuppressive agent are possible to increase the risk of developing CLL.

Signs, symptoms and treatments

CLL always accompanies multiple complicated symptoms, including infection, abnormal bleeding, shortness of breath, chill and swollen lymph nodes. The conventional treatments of CLL focus on disease control that achieves a chronic indolent status. During the past ten years, aggressive research in the understanding of CLL has generated innovative therapeutic approaches based on molecular biology.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.